Commentary

Video

Discussion of a Patient Case of Advanced BTC

Author(s):

Milind Javle, MD, The University of Texas MD Anderson Cancer CenterRachna T. Shroff, MD, MS, FASCO, University of Arizona Cancer Center

Milind Javle, MD, and Rachna Shroff, MD, MS, FASCO, discuss a case of advanced biliary tract cancer with a patient.

Related Videos
Ruihua Xu, MD, PhD, professor, medical oncology, Department of Medical Oncology, president, Sun Yat-sen University Cancer Center, chairman, Chinese Society of Clinical Oncology
Chih-Yi Liao, MD
Anthony B. El-Khoueiry, MD
Craig E. Devoe, MD, MS
Ciara Kelly, MBBCh, BAO
Ciara Kelly, MBBCh, BAO
Ciara Kelly, MBBCh, BAO
Ryan Hood, BA, MD/MPH student, University of Miami Miller School of Medicine
Samuel Cytryn, MD, and David B. Zhen, MD, discuss how immunotherapy plus chemotherapy has improved the durability of outcomes in advanced GI cancers.
Samuel Cytryn, MD, and David B. Zhen, MD, on factors for selecting nivolumab plus chemotherapy or ipilimumab in esophageal squamous cell carcinoma.
Related Content
State of Science Summit: Gastrointestinal Cancer - Chaired by: Tanios Bekaii-Saab, MD and Darshil Shah, MD, MPH
October 2nd 2024

State of Science Summit: Gastrointestinal Cancer - Chaired by: Tanios Bekaii-Saab, MD and Darshil Shah, MD, MPH

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

US FDA
September 26th 2024

ODAC Votes Against Risk:Benefit Profile of Frontline Anti–PD-1 Therapy in Metastatic/Unresectable ESCC With a PD-L1 Expression Under 1

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

The FDA has granted fast track designation to EO-3021 for use in select patients with claudin 18.2–expressing gastric or GEJ cancer.
September 24th 2024

FDA Grants Fast Track Status to EO-3021 for CLDN18.2-Expressing Gastric or GEJ Cancer

Gil Efron, chief executive officer, Purple Biotech
September 21st 2024

Phase 2 Data Point to Potential Predictive Biomarkers for Benefit With Second-Line CM24 Combo in PDAC